Patents by Inventor Xianrui Zhao

Xianrui Zhao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE
    Publication number: 20240109877
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4A, R4b, and R5, are as defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL.
    Type: Application
    Filed: March 21, 2023
    Publication date: April 4, 2024
    Inventors: Zhiguo Bian, Jason P. Burke, Zhaozhong J. Jia, Xingyu Jiang, Matthew H. Katcher, Venkat Reddy Mali, Violeta L. Marin, Elizabeth L. Noey, Akinori Okano, Alexey A. Rivkin, Spencer O. Scholz, Kevin R. Woller, Xianrui Zhao, Ashley M. Adams, Berenger Biannic, Shahab Mortezaei, Joshua N. Payette, Jeffery A. Zablocki
  • Kappa opioid receptor antagonists and products and methods related thereto
    Patent number: 11897873
    Abstract: Compounds are provided that antagonize the kappa-opioid receptor (KOR) and products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof: wherein X, Y, R1, R2, R4, R5, R6, R7, R8 and R11 are as defined herein.
    Type: Grant
    Filed: July 30, 2021
    Date of Patent: February 13, 2024
    Assignees: BLACKTHORN THERAPEUTICS, INC., THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Edward Roberts, Miguel A. Guerrero, Mariangela Urbano, Hugh Rosen, Robert M. Jones, Candace Mae Laxamana, Xianrui Zhao, Eric Douglas Turtle
  • KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO
    Publication number: 20220162202
    Abstract: Compounds are provided that antagonize the kappa-opioid receptor (KOR) and products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof. wherein X, Y, R1, R2, R4, R5, R6, R7, R8 and R11 are as defined herein.
    Type: Application
    Filed: July 30, 2021
    Publication date: May 26, 2022
    Inventors: Edward Roberts, Miguel A. Guerrero, Mariangela Urbano, Hugh Rosen, Robert M. Jones, Candace Mae Laxamana, Xianrui Zhao, Eric Douglas Turtle
  • Kappa opioid receptor antagonists and products and methods related thereto
    Patent number: 11124504
    Abstract: Compounds are provided that antagonize the kappa-opioid receptor (KOR) and products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof: wherein X, Y, R1, R2, R4, R5 R6, R7, R8 and R11 are as defined herein.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: September 21, 2021
    Assignees: THE SCRIPPS RESEARCH INSTITUTE, BLACKTHORN THERAPEUTICS, INC.
    Inventors: Edward Roberts, Miguel A. Guerrero, Mariangela Urbano, Hugh Rosen, Robert M. Jones, Candace Mae Laxamana, Xianrui Zhao, Eric Douglas Turtle
  • KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO
    Publication number: 20210047310
    Abstract: Compounds are provided that antagonize the kappa-opioid receptor (KOR) and products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof: wherein X, Y, R1, R2, R4, R5 R6, R7, R8 and R11 are as defined herein.
    Type: Application
    Filed: April 10, 2020
    Publication date: February 18, 2021
    Inventors: Edward Roberts, Miguel A. Guerrero, Mariangela Urbano, Hugh Rosen, Robert M. Jones, Candace Mae Laxamana, Xianrui Zhao, Eric Douglas Turtle
  • Kappa opioid receptor antagonists and products and methods related thereto
    Patent number: 10676469
    Abstract: Compounds are provided that antagonize the kappa-opioid receptor (KOR) and products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof: wherein X, Y, R1, R2, R4, R5 R6, R7, R8 and R11 are as defined herein.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: June 9, 2020
    Assignees: BLACKTHORN THERAPEUTICS, INC., THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Edward Roberts, Miguel A. Guerrero, Mariangela Urbano, Hugh Rosen, Robert M. Jones, Candace Mae Laxamana, Xianrui Zhao, Eric Douglas Turtle
  • KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO
    Publication number: 20190023700
    Abstract: Compounds are provided that antagonize the kappa-opioid receptor (KOR) and products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof: wherein X, Y, R1, R2, R4, R5 R6, R7, R8 and R11 are as defined herein.
    Type: Application
    Filed: March 16, 2018
    Publication date: January 24, 2019
    Inventors: Edward Roberts, Miguel A. Guerrero, Mariangela Urbano, Hugh Rosen, Robert M. Jones, Candace Mae Laxamana, Xianrui Zhao, Eric Douglas Turtle
  • Substituted dipyridylamines and uses thereof
    Patent number: 9399636
    Abstract: The present invention provides for compounds of Formula I and various embodiments thereof, and compositions comprising compounds of Formula I and various embodiments thereof. In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6, m, n and the C-linked Ring have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula I as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: July 26, 2016
    Assignee: Genentech, Inc.
    Inventors: Frederick Cohen, Malcolm Huestis, Cuong Ly, Snahel Patel, Michael Siu, Xianrui Zhao
  • SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF
    Publication number: 20150080367
    Abstract: The present invention provides for compounds of Formula I and various embodiments thereof, and compositions comprising compounds of Formula I and various embodiments thereof. In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6, m, n and the C-linked Ring have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula I as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Applicant: Genentech, Inc.
    Inventors: Frederick Cohen, Malcolm Huestis, Cuong Ly, Snahel Patel, Michael Siu, Xianrui Zhao
  • PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    Publication number: 20120165313
    Abstract: Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).
    Type: Application
    Filed: March 1, 2012
    Publication date: June 28, 2012
    Applicant: Genentech, Inc.
    Inventors: Philippe Bergeron, Frederick Cohen, Anthony Estrada, Michael F.T. Koehler, Kevin Hon Luen Lau, Coung Ly, Joseph P. Lyssikatos, Daniel Ortwine, Zhonghua Pei, Xianrui Zhao
  • Pyrimidine compounds, compositions and methods of use
    Patent number: 8163763
    Abstract: Disclosed are compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: April 24, 2012
    Assignee: Genentech, Inc.
    Inventors: Philippe Bergeron, Frederick Cohen, Anthony Estrada, Michael F. T. Koehler, Kevin Hon Luen Lau, Cuong Ly, Joseph P. Lyssikatos, Daniel Ortwine, Zhonghua Pei, Xianrui Zhao
  • OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    Publication number: 20100331305
    Abstract: Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).
    Type: Application
    Filed: June 23, 2010
    Publication date: December 30, 2010
    Applicant: Genentech, Inc.
    Inventors: Philippe Bergeron, Frederick Cohen, Anthony Estrada, Michael F.T. Koehler, Cuong Ly, Joseph P. Lyssikatos, Zhonghua Pei, Wendy Lee, Xianrui Zhao
  • PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    Publication number: 20100069357
    Abstract: Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).
    Type: Application
    Filed: July 31, 2009
    Publication date: March 18, 2010
    Applicant: Genentech, Inc.
    Inventors: Philippe Bergeron, Frederick Cohen, Anthony Estrada, Michael F.T. Koehler, Kevin Hon Luen Lau, Cuong Ly, Joseph P. Lyssikatos, Daniel Ortwine, Zhonghua Pei, Xianrui Zhao